Elixiron’s Enrupatinib Shows Neuroinflammation Reduction in Phase 2 Alzheimer’s Trial
Elixiron's enrupatinib reduced neuroinflammation signals by over 30% in biomarker-selected Alzheimer's patients within 28 days of dosing.
IMAAVY meets primary endpoint in Phase 2/3 warm autoimmune hemolytic anemia trial
Nipocalimab met its primary endpoint in the Phase 2/3 ENERGY trial for warm autoimmune hemolytic anemia, with nearly two-thirds...
Novartis del-brax meets primary endpoints in FSHD Phase I/II study
Novartis del-brax Phase I/II study met primary endpoints, reducing KHDC1L and creatine kinase in FSHD patients over 12 months...
Health Canada Grants Priority Review to Italfarmaco’s Givinostat for Duchenne Muscular Dystrophy
Health Canada grants Priority Review to Italfarmaco's Givinostat for Duchenne muscular dystrophy, with a 180-day regulatory decision target by...
Kymera’s KT-485 Enters Phase 1 Trial Under $20M Sanofi Deal
Kymera's KT-485 enters Phase 1 testing for hidradenitis suppurativa under a $20M Sanofi partnership with up to $975M in...
TG Therapeutics Begins Phase 2 Trial of BRIUMVI in Myasthenia Gravis
TG Therapeutics launches Phase 2 trial of BRIUMVI in myasthenia gravis, testing sequential therapy with efgartigimod for sustained B-cell...
FDA Approves Lilly’s EBGLYSS for Every-Eight-Week Dosing in Atopic Dermatitis
FDA approves every-eight-week dosing for Lilly's EBGLYSS in atopic dermatitis, reducing injections to six per year for adults and...
Alkeus Starts Phase 3 Trial of Gildeuretinol for Stargardt Disease
Alkeus starts Phase 3 NORTHSTAR trial of gildeuretinol for Stargardt disease, enrolling 230 patients across 55 sites in 11...
Ambros Starts CRPS-RISE Phase 3 Trial of Neridronate for Complex Regional Pain Syndrome
Ambros launches CRPS-RISE Phase 3 trial of neridronate for complex regional pain syndrome, enrolling 270 patients with warm-phase CRPS-1.
Potravitug Shows Improved Viral Clearance in BKPyV Kidney Transplant Trial
Potravitug shows improved viral clearance in BKPyV kidney transplant trial, with 64% achieving one-log reduction by week 20 versus...